Molecular Profiles Invests in Hot Melt Extrusion Technology - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Molecular Profiles Invests in Hot Melt Extrusion Technology

Molecular Profiles, a UK-based pharmaceutical development and manufacturing services provider, has invested in GMP hot melt extrusion (HME) technology along with other milling equipment. The expansion is part of a wider project focusing on enabling technologies to accelerate formulation development, particularly for complex molecules that are difficult to progress.

Rob Harris, chief technical officer at Molecular Profiles, said in a press statement that expanding the company’s in-house equipment would complement its expertise by bringing on-stream a diverse range of enabling technologies to assist drug developers in developing challenging compounds. According to Harris, the new enabling technologies division forms the backbone of the company’s early formulation development services, which primarily specialize in screening formulation options for challenging compounds, developing effective formulations, and finding solutions to meet clients’ product development requirements.

This investment marked a significant venture for Molecular Profiles. The company opened its new clinical production site in July 2013 following a successful inspection from the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Molecular Profiles manufactures a range of dosage forms for clinical trials spanning solids, liquids, semi-solids and inhaled products, including potent compounds.

Source: Molecular Profiles


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here